litlas
ログインアカウント作成

Richard Pazdur

1987–2025 年に発表

321
論文数
55,756
被引用数
134
h 指数
312
i10 指数

被引用数

Richard Pazdur の年別被引用数1948 年: 被引用 3 件1987 年: 被引用 1 件1989 年: 被引用 4 件1990 年: 被引用 4 件1991 年: 被引用 8 件1992 年: 被引用 9 件1993 年: 被引用 7 件1994 年: 被引用 20 件1995 年: 被引用 18 件1996 年: 被引用 25 件1997 年: 被引用 14 件1998 年: 被引用 21 件1999 年: 被引用 31 件2000 年: 被引用 31 件2001 年: 被引用 57 件2002 年: 被引用 66 件2003 年: 被引用 84 件2004 年: 被引用 138 件2005 年: 被引用 185 件2006 年: 被引用 175 件2007 年: 被引用 169 件2008 年: 被引用 219 件2009 年: 被引用 263 件2010 年: 被引用 266 件2011 年: 被引用 238 件2012 年: 被引用 237 件2013 年: 被引用 227 件2014 年: 被引用 300 件2015 年: 被引用 320 件2016 年: 被引用 328 件2017 年: 被引用 404 件2018 年: 被引用 472 件2019 年: 被引用 1,753 件2020 年: 被引用 2,279 件2021 年: 被引用 2,416 件2022 年: 被引用 2,162 件2023 年: 被引用 1,752 件2024 年: 被引用 2,830 件2025 年: 被引用 1,413 件2026 年: 被引用 52 件1949〜1986 年は被引用が無いため表示していません1988 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 6,884 件、この内訳の 27%中国: 引用元論文 3,048 件、この内訳の 11.9%イタリア: 引用元論文 1,504 件、この内訳の 5.9%イギリス: 引用元論文 1,312 件、この内訳の 5.1%ドイツ: 引用元論文 1,304 件、この内訳の 5.1%フランス: 引用元論文 1,004 件、この内訳の 3.9%スペイン: 引用元論文 819 件、この内訳の 3.2%カナダ: 引用元論文 801 件、この内訳の 3.1%日本: 引用元論文 686 件、この内訳の 2.7%オランダ: 引用元論文 617 件、この内訳の 2.4%インド: 引用元論文 607 件、この内訳の 2.4%オーストラリア: 引用元論文 578 件、この内訳の 2.3%
0%27%その他 25%

機関

分野

  • Medicine65.2%
  • Biochemistry, Genetics and Molecular Biology23.5%
  • Immunology and Microbiology2.8%
  • Materials Science1.7%
  • Computer Science1.1%
  • Engineering1.1%
  • その他4.6%

トピック

  • Cancer Immunotherapy and Biomarkers5.7%
  • CAR-T cell therapy research3%
  • Lung Cancer Treatments and Mutations3%
  • HER2/EGFR in Cancer Research3%
  • Breast Cancer Treatment Studies2.7%
  • Cancer Genomics and Diagnostics2.2%
  • その他80.4%

共著者

全論文

検索で開く
  1. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    著者: Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P. Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa, Sandra M. Swain, Tatiana M. Prowell, Sibylle Loibl, D. Lawrence Wickerham, Jan Bogaerts, José Baselga, Charles M. Perou, Gideon M. Blumenthal, Jens‐Uwe Blohmer, Eleftherios P. Mamounas, Jonas Bergh, Semiglazov Vf, Robert Justice, Holger Eidtmann, Soonmyung Paik, Martine Piccart, Rajeshwari Sridhara, Peter A. Fasching, Leen Slaets, Shenghui Tang, Bernd Gerber, Charles E. Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, W. Eiermann, Gϋnter von Minckwitz - The Lancet 2014 被引用: 4,710

  2. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors

    著者: Leigh Marcus, Lola A. Fashoyin‐Aje, Martha Donoghue, Mengdie Yuan, Lisa Rodríguez, Pamela Gallagher, Reena Philip, Soma Ghosh, Marc R. Theoret, Julia A. Beaver, Richard Pazdur, Steven J. Lemery - Clinical Cancer Research 2021 被引用: 568

  3. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

    著者: Leigh Marcus, Steven J. Lemery, Patricia Keegan, Richard Pazdur - Clinical Cancer Research 2019 被引用: 1,154

  4. Trends in the approval of cancer therapies by the FDA in the twenty-first century

    著者: Emma Scott, Andrea Baines, Yutao Gong, Rodney Moore, Gülsüm Emel Pamuk, Haleh Saber, Ashim Subedee, Matthew D. Thompson, Wenming Xiao, Richard Pazdur, V. Ashutosh Rao, Julie A. Schneider, Julia A. Beaver - Nature Reviews Drug Discovery 2023 被引用: 269

  5. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

    著者: Robert Q. Le, Liang Li, Weishi Yuan, Stacy S. Shord, Lei Nie, Bahru Habtemariam, Donna Przepiorka, Ann T. Farrell, Richard Pazdur - The Oncologist 2018 被引用: 882

  6. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

    著者: Jaleh Fallah, Sundeep Agrawal, Haley Gittleman, Mallorie H. Fiero, Sriram Subramaniam, Christy S. John, Wei Chen, Tiffany K. Ricks, Gang Niu, Anthony F. Fotenos, Min Wang, Kelly Chiang, William F. Pierce, Daniel L. Suzman, Shenghui Tang, Richard Pazdur, Laleh Amiri‐Kordestani, Amna Ibrahim, Paul G. Kluetz - Clinical Cancer Research 2022 被引用: 220

  7. FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC

    著者: Erica C. Nakajima, Nicole Drezner, Xiaoxue Li, Pallavi S. Mishra‐Kalyani, Yajun Liu, Hong Zhao, Youwei Bi, Jiang Liu, Atiqur Rahman, Emily Wearne, Idara Ojofeitimi, Lauren Tesh Hotaki, Dianne Spillman, Richard Pazdur, Julia A. Beaver, Harpreet Singh - Clinical Cancer Research 2021 被引用: 305

  8. FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma

    著者: Bhupinder Mann, John R. Johnson, Martin H. Cohen, Robert Justice, Richard Pazdur - The Oncologist 2007 被引用: 1,353

  9. FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

    著者: Maura O’Leary, Xiaobin Lü, Ying Huang, Xue Lin, Iftekhar Mahmood, Donna Przepiorka, Denise Gavin, Shiowjen Lee, Ke Liu, Bindu George, Wilson W. Bryan, Marc R. Theoret, Richard Pazdur - Clinical Cancer Research 2018 被引用: 291

  10. The Drug-Dosing Conundrum in Oncology — When Less Is More

    著者: Mirat Shah, Atiqur Rahman, Marc R. Theoret, Richard Pazdur - New England Journal of Medicine 2021 被引用: 278

  11. FDA Approval: Blinatumomab

    著者: Donna Przepiorka, Chia‐Wen Ko, Albert Deisseroth, Carolyn L. Yancey, Reyes Candau-Chacon, Haw-Jyh Chiu, Brenda J. Gehrke, Candace Gomez-Broughton, Robert C. Kane, Susan Kirshner, Nitin Mehrotra, Tiffany K. Ricks, Deborah H. Schmiel, Pengfei Song, Ping Zhao, Qing Zhou, Ann T. Farrell, Richard Pazdur - Clinical Cancer Research 2015 被引用: 364

  12. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia

    著者: Kelly J. Norsworthy, Chia‐Wen Ko, Jee Eun Lee, Jiang Liu, Christy S. John, Donna Przepiorka, Ann T. Farrell, Richard Pazdur - The Oncologist 2018 被引用: 259

  13. FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

    著者: Sakar Wahby, Lola A. Fashoyin‐Aje, Christy Osgood, Joyce Cheng, Mallorie H. Fiero, Lijun Zhang, Shenghui Tang, Salaheldin S. Hamed, Pengfei Song, Rosane Charlab, Sarah E. Dorff, Tiffany K. Ricks, Kimberly Barnett-Ringgold, Jeannette Dinin, Kirsten B. Goldberg, Marc R. Theoret, Richard Pazdur, Laleh Amiri‐Kordestani, Julia A. Beaver - Clinical Cancer Research 2020 被引用: 150

  14. Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients

    著者: Jeanne Fourie Zirkelbach, Mirat Shah, Jonathon Vallejo, Joyce Cheng, Amal Ayyoub, Jiang Liu, Rachel Hudson, Rajeshwari Sridhara, Gwynn Ison, Laleh Amiri‐Kordestani, Shenghui Tang, Thomas Gwise, Atiqur Rahman, Richard Pazdur, Marc R. Theoret - Journal of Clinical Oncology 2022 被引用: 165

  15. FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer

    著者: Preeti Narayan, Christy Osgood, Harpreet Singh, Haw-Jyh Chiu, Tiffany K. Ricks, Edwin C.Y. Chow, Junshan Qiu, Pengfei Song, Jingyu Yu, Frances Namuswe, Maria Guiterrez-Lugo, Sherry Hou, William F. Pierce, Kirsten B. Goldberg, Shenghui Tang, Laleh Amiri‐Kordestani, Marc R. Theoret, Richard Pazdur, Julia A. Beaver - Clinical Cancer Research 2021 被引用: 164

  16. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer

    著者: Shaily Arora, Sanjeeve Balasubramaniam, Hui Zhang, Tara Berman, Preeti Narayan, Daniel L. Suzman, Erik Bloomquist, Shenghui Tang, Yutao Gong, Rajeshwari Sridhara, Francisca Reyes Turcu, Deb Chatterjee, Banu Saritas-Yildirim, Soma Ghosh, Reena Philip, Anand Pathak, Jennifer Gao, Laleh Amiri‐Kordestani, Richard Pazdur, Julia A. Beaver - The Oncologist 2020 被引用: 182

  17. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer

    著者: Julia A. Beaver, Laleh Amiri‐Kordestani, Rosane Charlab, Wei Chen, Todd R. Palmby, Amy Tilley, Jeanne Fourie Zirkelbach, Jingyu Yu, Qi Liu, Liang Zhao, Joyce Z. Crich, Xiao Hong Chen, Minerva Hughes, Erik Bloomquist, Shenghui Tang, Rajeshwari Sridhara, Paul G. Kluetz, Geoffrey Kim, Amna Ibrahim, Richard Pazdur, Patricia Cortazar - Clinical Cancer Research 2015 被引用: 372

  18. Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

    著者: V. Ellen Maher, Laura L. Fernandes, Chana Weinstock, Shenghui Tang, Sundeep Agarwal, Michael H. Brave, Yang‐Min Ning, Harpreet Singh, Daniel L. Suzman, James Xu, Kirsten B. Goldberg, Rajeshwari Sridhara, Amna Ibrahim, Marc R. Theoret, Julia A. Beaver, Richard Pazdur - Journal of Clinical Oncology 2019 被引用: 346

  19. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors

    著者: Jaleh Fallah, Michael H. Brave, Chana Weinstock, Gautam U. Mehta, Diana Bradford, Haley Gittleman, Erik Bloomquist, Rosane Charlab, Salaheldin S. Hamed, Claudia P. Miller, Sarah E. Dorff, Wiley Chambers, Bronwyn D. Mixter, Jeannette Dinin, William F. Pierce, Tiffany K. Ricks, Shenghui Tang, Martha Donoghue, Richard Pazdur, Laleh Amiri‐Kordestani, Amna Ibrahim, Julia A. Beaver - Clinical Cancer Research 2022 被引用: 171

  20. FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer

    著者: Asma Dilawari, Mirat Shah, Gwynn Ison, Haley Gittleman, Mallorie H. Fiero, Ankit Shah, Salaheldin S. Hamed, Junshan Qiu, Jingyu Yu, Wimolnut Manheng, Tiffany K. Ricks, Rajan Pragani, Arulvathani Arudchandran, Paresma Patel, Shadia Zaman, Arpita Roy, Shyam Kalavar, Soma Ghosh, William F. Pierce, Nam Atiqur Rahman, Shenghui Tang, Bronwyn D. Mixter, Paul G. Kluetz, Richard Pazdur, Laleh Amiri‐Kordestani - Clinical Cancer Research 2023 被引用: 105

  21. FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

    著者: Geoffrey Kim, Gwynn Ison, Amy E. McKee, Hui Zhang, Shenghui Tang, Thomas Gwise, Rajeshwari Sridhara, Eunice Lee, Abraham Tzou, Reena Philip, Haw-Jyh Chiu, Tiffany K. Ricks, Todd R. Palmby, Anne‐Marie Russell, Gaétan Ladouceur, Elimika Pfuma, Hongshan Li, Liang Zhao, Qi Liu, Rajesh Venugopal, Amna Ibrahim, Richard Pazdur - Clinical Cancer Research 2015 被引用: 527

  22. FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

    著者: Elaine Chang, Chana Weinstock, Lijun Zhang, Rosane Charlab, Sarah E. Dorff, Yutao Gong, Vicky Hsu, Fang Li, Tiffany K. Ricks, Pengfei Song, Shenghui Tang, Peter Waldron, Jingyu Yu, Eias Zahalka, Kirsten B. Goldberg, Richard Pazdur, Marc R. Theoret, Amna Ibrahim, Julia A. Beaver - Clinical Cancer Research 2020 被引用: 183

  23. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

    著者: Jennifer Gao, Joyce Cheng, Erik Bloomquist, Jacquelyn Sanchez, Suparna Wedam, Harpreet Singh, Laleh Amiri‐Kordestani, Amna Ibrahim, Rajeshwari Sridhara, Kirsten B. Goldberg, Marc R. Theoret, Paul G. Kluetz, Gideon M. Blumenthal, Richard Pazdur, Julia A. Beaver, Tatiana M. Prowell - The Lancet Oncology 2019 被引用: 297

  24. FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

    著者: Laleh Amiri‐Kordestani, Gideon M. Blumenthal, Qiang Xu, Lijun Zhang, Shenghui Tang, Linan Ha, Wendy C. Weinberg, Bo Chi, Reyes Candau-Chacon, P. E. Hughes, Anne‐Marie Russell, Sarah Pope Miksinski, Xiao Hong Chen, W. David McGuinn, Todd R. Palmby, Sarah J. Schrieber, Qi Liu, Jian Wang, Pengfei Song, Nitin Mehrotra, Lisa Skarupa, Kathleen A. Clouse, Ali Al‐Hakim, Rajeshwari Sridhara, Amna Ibrahim, Robert Justice, Richard Pazdur, Patricia Cortazar - Clinical Cancer Research 2014 被引用: 345